More than 800 Women in Europe and Japan Have Received Motiva Implant Matrix Breast Implants with VeriTeQ’s Q Inside Safety Technology in Past Four Months
VeriTeQ’s CEO Scott R. Silverman to present today at RedChip Companies’ Global Online CEO Conference at 11 am ET
July 17, 2014 09:00 AM Eastern Daylight Time
DELRAY BEACH, Fla.–(BUSINESS WIRE)–VeriTeQ Corporation (“VeriTeQ”) (OTC Markets: VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that the adoption of its Q Inside Safety Technology™ continues to increase across Europe. There are now more than 800 women in Europe and Japan who have received Motiva Implant Matrix® breast implants, manufactured by VeriTeQ’s customer Establishment Labs, S.A. (“EL”), with VeriTeQ’s Q Inside Safety Technology. Motiva Implant Matrix® breast implants with Q Inside Safety Technology can be safely and accurately identified from outside of the body in a physician’s office.
VeriTeQ’s FDA cleared Q Inside Safety Technology acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology may also provide an extra level of protection to the patient in the event of a recall or other safety event.
EL’s Motiva Implant Matrix® Ergonomix™, VelvetSurface® PLUS, and SilkSurface® PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval, which enables EL to market its Motiva Implant Matrix® breast implants to patients in 28 countries in the European Union.
“We are pleased with the widespread physician and patient acceptance of the combination of EL’s advanced breast implants and our important medical device identification technology,” said Scott R. Silverman, VeriTeQ’s Chairman and Chief Executive Officer. “We believe that Q Inside Safety Technology sets EL’s Motiva Implant Matrix® breast implants apart from its competitors, offering distinct advantages when it comes to both patient safety and device quality.”
Mr. Silverman will present today at 11:00 am ET RedChip Companies’ Global Online CEO Conference. To listen to the presentation and participate in the live question and answer session, please visit http://www.redchip.com.
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
Establishment Labs is a privately held, global breast, body and facial aesthetic company with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com.
Statements in this press release about our future expectations, including the likelihood that Q Inside Safety Technology may also provide an extra level of protection to the patient in the event of a recall or other safety event; the likelihood that Q Inside Safety Technology sets EL’s Motiva Implant Matrix® breast implants apart from its competitors, offering distinct advantages when it comes to both patient safety and device quality; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 15, 2014, and Forms 10-Q, filed on May 14, 2014, November 14, 2013, and August 9, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.